EDSA on XNAS, Health Care, Edesa Biotech, Inc., job postings
Measures activity, not value. Not investment advice.
Stock is down 81% in six months while cash of $10.3M sits against a $14.1M annual loss.
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Jun 2026
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
expected around 11 Dec 2026 (an estimate: a year ago it reported on 12 Dec 2025)
Revenue and net income per quarter. Quarter to 30 Jun 2026: net loss $5.4M.
31 Dec 2021RevenueNet incomeNet losstallest bar $5.8M30 Jun 2026
See the numbers
Quarter to
Revenue
Net income
30 Jun 2026
–
-$5.4M
31 Mar 2026
–
-$4.2M
31 Dec 2025
–
-$2.2M
30 Sep 2025
–
-$2.2M
30 Jun 2025
–
-$1.7M
31 Mar 2025
–
-$1.6M
31 Dec 2024
–
-$1.6M
30 Sep 2024
–
-$962K
30 Jun 2024
–
-$1.7M
31 Mar 2024
–
-$1.9M
31 Dec 2023
–
-$1.7M
30 Sep 2023
–
-$1.7M
30 Jun 2023
–
-$2.0M
31 Mar 2023
–
-$2.3M
31 Dec 2022
–
-$2.3M
30 Sep 2022
–
-$2.8M
30 Jun 2022
–
-$5.8M
31 Mar 2022
–
-$4.6M
31 Dec 2021
–
-$4.4M
Fundamentals, 12 months to 30 Jun 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$14.1M
-$5.9M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-123%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$10.3M
$12.4M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$10.3M (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.91
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.2
2.0
Latest = 12 months to 30 Jun 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
0%
34 13F filers vs 34
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
76%
7.3M shares held by 13F filers (30 Sep 2026) of 9.6M outstanding (13 Aug 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
1.6%
158K shares sold short (30 Oct 2026) of 9.6M outstanding (13 Aug 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
4.0
158K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-2.0%
161K shares sold short in the report before, 158K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
38%
38% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 40%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
0
0 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
0 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $2.00 on 20 Nov 2026, +16% over 12 months (12-month range $0.80 to $18.27)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $233K in the last 12 months (the 12 months before: $0).Revenue per quarter. Revenue $0 in the latest quarter.Capital spending per quarter. Capital spending $0 in the latest quarter.Institutional holders (13F filers). 34 13F filers reported holding it in the latest 13F quarter, +55% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 30 Sep 2021: $0; public on 29 Dec 2021
Capital spending per quarter
Quarter ended 31 Dec 2021: $3K, +177% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $1K, -60% on a year earlier; public on 14 May 2022
Quarter ended 30 Jun 2022: $1K, -61% on a year earlier; public on 13 Aug 2022
Quarter ended 31 Dec 2022: $0, -100% on a year earlier; public on 11 Feb 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $0; public on 16 Dec 2023
Institutional holders (13F filers)
31 Dec 2021 report: 22; public on 14 Feb 2022
31 Mar 2022 report: 20; public on 16 May 2022
30 Jun 2022 report: 21; public on 15 Aug 2022
30 Sep 2022 report: 18; public on 14 Nov 2022
31 Dec 2022 report: 20; public on 14 Feb 2023
31 Mar 2023 report: 24; public on 15 May 2023
30 Jun 2023 report: 19; public on 14 Aug 2023
30 Sep 2023 report: 17; public on 14 Nov 2023
31 Dec 2023 report: 18; public on 14 Feb 2024
31 Mar 2024 report: 17; public on 15 May 2024
30 Jun 2024 report: 17; public on 14 Aug 2024
30 Sep 2024 report: 17; public on 14 Nov 2024
31 Dec 2024 report: 15; public on 14 Feb 2025
31 Mar 2025 report: 19; public on 15 May 2025
30 Jun 2025 report: 17; public on 14 Aug 2025
30 Sep 2025 report: 22; public on 14 Nov 2025
31 Dec 2025 report: 22; public on 17 Feb 2026
31 Mar 2026 report: 28; public on 15 May 2026
30 Jun 2026 report: 34; public on 14 Aug 2026
30 Sep 2026 report: 34; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is net income, quarter at -$5.4M (30 Jun 2026), 212% below its normal quarter of -$1.7M; higher than 6% of its own history.
In 12 months: 3 director or officer changes, 3 major agreements, 1 private placement, 1 agreement ended. Results releases and routine reports are left out.
Filed
What happened
Source
9 Nov 2026
Granted Kyorin Pharmaceutical Co., Ltd. exclusive Japan license to paridiprubart for ARDS; $12M upfront, up to $55M development milestones; A major agreement ended
had 514K shares sold short in the 30 Apr 2026 report, 13× the same report last year.
Same report last year: 41K; its normal report is 26K.
See the evidence
This period
514K (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
26K
Typical spread (median absolute deviation)
18K
How far from its usual level
+9.7
Same report last year
41K
History used
2,512 days
the 30 Apr 2026 report24 earlier reportsnormal: 26K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 603K shares sold short in the 13 Mar 2026 report, 6.2× the same report last year.
Same report last year: 97K; its normal report is 26K.
See the evidence
This period
603K (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
26K
Typical spread (median absolute deviation)
18K
How far from its usual level
+11.5
Same report last year
97K
History used
2,464 days
the 13 Mar 2026 report24 earlier reportsnormal: 26K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 27 Feb 2026 report, 13× the same report last year.
Same report last year: 107K; its normal report is 26K.
See the evidence
This period
1.4M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
26K
Typical spread (median absolute deviation)
18K
How far from its usual level
+27.7
Same report last year
107K
History used
2,450 days
the 27 Feb 2026 report24 earlier reportsnormal: 26K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 852K shares sold short in the 14 Feb 2025 report, 56× the same report last year.
Same report last year: 15K; its normal report is 17K.
See the evidence
This period
852K (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
17K
Typical spread (median absolute deviation)
1,582
How far from its usual level
+16.7
Same report last year
15K
History used
2,072 days
the 14 Feb 2025 report24 earlier reportsnormal: 17K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 906K shares sold short in the 31 Mar 2023 report, 6.8× the same report last year.
Same report last year: 134K; its normal report is 150K.
See the evidence
This period
906K (the 31 Mar 2023 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
116K
How far from its usual level
+4.4
Same report last year
134K
History used
1,386 days
the 31 Mar 2023 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 817K shares sold short in the 15 Mar 2023 report, 3.5× the same report last year.
Same report last year: 233K; its normal report is 150K.
See the evidence
This period
817K (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
93K
How far from its usual level
+4.8
Same report last year
233K
History used
1,370 days
the 15 Mar 2023 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 685K shares sold short in the 28 Feb 2023 report, 2.5× the same report last year.
Same report last year: 271K; its normal report is 150K.
See the evidence
This period
685K (the 28 Feb 2023 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
93K
How far from its usual level
+3.9
Same report last year
271K
History used
1,355 days
the 28 Feb 2023 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 644K shares sold short in the 15 Feb 2023 report, 2.2× the same report last year.
Same report last year: 296K; its normal report is 150K.
See the evidence
This period
644K (the 15 Feb 2023 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
93K
How far from its usual level
+3.6
Same report last year
296K
History used
1,342 days
the 15 Feb 2023 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 782K shares sold short in the 31 Jan 2023 report, 2.4× the same report last year.
Same report last year: 323K; its normal report is 150K.
See the evidence
This period
782K (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
93K
How far from its usual level
+4.6
Same report last year
323K
History used
1,327 days
the 31 Jan 2023 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 670K shares sold short in the 13 Jan 2023 report, 2.3× the same report last year.
Same report last year: 297K; its normal report is 150K.
See the evidence
This period
670K (the 13 Jan 2023 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
93K
How far from its usual level
+3.8
Same report last year
297K
History used
1,309 days
the 13 Jan 2023 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 815K shares sold short in the 30 Dec 2022 report, 3.0× the same report last year.
Same report last year: 270K; its normal report is 150K.
See the evidence
This period
815K (the 30 Dec 2022 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
93K
How far from its usual level
+4.8
Same report last year
270K
History used
1,295 days
the 30 Dec 2022 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 104 entries; narrow the window or the kind of data to see older ones.
Not listed: 160 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001540159
Ticker
EDSA
Domain
edesabiotech.com
Hq location
|TORONTO|M5H 2 (1 unverified)
Name
Edesa Biotech, Inc., Stellar Biotechnologies, Inc.
SEC Form 13F institutional holdings270 data points30 Jun 2019 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)195 records20 Jan 2016 to 17 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)731 data points31 Aug 2011 to 13 Aug 2026
SEC Form 4 insider transactions45 records, 156 data points14 Mar 2018 to 11 Mar 2026
FINRA short interest (twice monthly)531 data points14 Jun 2019 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3744 data points10 Jun 2019 to 20 Nov 2026